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Background: Therapeutic drug monitoring (TDM) of inflix-
imab (IFX) trough levels and anti-drug antibodies in conjunc-
tion with symptoms, disease history, and investigations can 
aid decision-making. This study evaluated 1-year outcomes 
of patients with decisions that were altered on the basis of 
TDM results, in order to investigate whether outcomes from 
TDM-based decisions to adjust or stop IFX treatment are du-
rable. Methods: We retrospectively collected clinical out-
comes 12 months post treatment decisions based on proac-
tive TDM. Patients whose initial treatment decisions were 
altered on the basis of TDM results were compared with 
those where the decision remained unchanged. Events of 
interest were inpatient admissions with active inflammatory 
bowel disease (IBD), further changes to biologic therapy, and 
IBD-related health-care costs. Results: Of 189 patients, 54 
(28%) had initial treatment decisions altered in the light of 
TDM results. The 135 patients whose initial decision was not 
altered in light of TDM results served as the comparator. 
There were no differences in hospitalization rates or subse-
quent biologic switches between the altered decision groups 
and the comparator group. IBD-related health-care costs 
were higher in those whose initial decision was altered (me-
dian GBP 7,912 vs. GBP 6,521; p < 0.0001) due to higher drug 
costs (median GBP 7,062 vs. GBP 6,012; p < 0.0001). Conclu-
sion: Our study demonstrates good outcomes from changes 
to IFX treatment based on TDM. Patients with a decision to 
stop, switch, or continue with an adjusted IFX dose experi-
enced comparable clinical outcomes but had higher drug-
related expenditure than those whose treatment decision 
was not altered in light of TDM. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Advances in the treatment of inflammatory bowel dis-
ease (IBD) have led to the widespread use of biologic ther-
apies [1]. The most commonly used biologics include the 
TNF-α inhibitors infliximab (IFX) and adalimumab, with 
increasing use of more recent biologic agents including 
vedolizumab and ustekinumab [1]. Although up to 85% 
of patients with IBD show clinical response to the TNF-α 
inhibitors, initial non-response (primary non-response) 
or a subsequent loss/reduced clinical response (second-
ary loss of response) remains a challenge [2–4]. In addi-
tion, approximately 5% of patients experience infusion-
related reactions [4]. These scenarios present physicians 
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with difficult management decisions. Although anti-
TNF-α therapy may reduce costs from hospitalizations 
and health-care encounters, overall drug costs are high 
[5].
The ability to predict response to anti-TNF-α therapy 
more accurately and optimize dosing regimens could re-
duce long-term costs and achieve remission in a greater 
proportion of patients. Therapeutic drug monitoring 
(TDM) of IFX trough levels and anti-drug antibodies 
(ADAs) can aid decision-making, but the role of TDM in 
routine clinical practice remains poorly defined [6–9]. 
The use of IFX trough levels along with ADAs provides 
key insights into the likely response, or lack thereof, to 
anti-TNF-α therapies [10]. Although there is good evi-
dence that secondary loss of response is best managed 
with the aid of TDM [11], the role of proactive TDM to 
guide decision-making remains more controversial [11, 
12]. A randomized controlled trial failed to demonstrate 
clinical benefits, but optimization of TDM prior to ran-
domization may have led to negative results or a type II 
statistical error may have occurred [9].
In addition, despite the availability of biosimilars, IFX 
remains far more expensive, than traditional treatment 
options. In a previous study, we demonstrated that among 
191 patients, IFX trough levels were frequently outside 
the therapeutic range in almost 50% of patients, and 
ADAs were present in 30.4% [13]. Treatment decisions 
were changed in the light of knowledge of the results of 
TDM in 29% of cases [13].
The aim of the current study was to evaluate the 
12-month clinical outcomes and health-care costs of pa-
tients who had their initial treatment decision altered 
based on knowledge of TDM results, compared with pa-
tients where the initial treatment decision remained the 
same, even when the results of TDM were known. Some 
clinicians are not convinced that TDM contributes to the 
management of patients in clinical remission and have 
expressed potential concerns over altering IFX treatment 
based on results of TDM. Patients who are in clinical re-
mission with an unfavourable TDM profile of low trough 
levels and high ADAs who stop IFX could, in theory, be 
at higher risk of disease recurrence (hospitalization or 
subsequent switch to another biologic agent). Addition-
ally, patients experiencing active inflammation with an 
unfavourable TDM profile of low trough levels and high 
ADAs are at high risk of IFX treatment failure [10, 14]. 
Switching these to an alternative anti-TNF will likely im-
prove their clinical status but could again in theory wors-
en their clinical outcomes. We therefore aimed to dem-
onstrate that those patients whose initial treatment deci-
sions were altered did not experience a higher rate of 
disease deterioration. On the assumption that clinical de-
cision-making based on proactive TDM ensures all pa-
tients are on appropriate medical therapy, our a priori 
hypothesis was that there would be no difference in clin-
ical outcomes between the groups whose initial treatment 
decision was altered based on the knowledge of results of 
TDM and the group where the treatment decision was not 
altered.
Methods
The current study provides 12-month follow-up data in a co-
hort of patients previously described [13]. Initially, patients with 
IBD established on IFX were reviewed in a virtual biologics clinic 
during 2016–2017. Virtual biologics clinics are used at our institu-
tion to review every patient on a biologic therapy remotely on an-
nual basis. Decisions to continue, stop, adjust, or switch biologic 
therapy are taken by a team of gastroenterologists and IBD special-
ist nurses. This multidisciplinary team (MDT) initially made 
blinded treatment decisions, without the knowledge of each pa-
tient’s TDM results, and based only on routine clinical informa-
tion, including recent outpatient clinic reviews, biochemistry, and 
imaging and/or endoscopy results. This first decision was then re-
corded. The results of TDM were then made available to the MDT, 
and a second decision, incorporating these results, was then re-
corded, which may have been altered in the light of the TDM re-
sults. The following TDM-based treatment algorithm was applied 
(Fig. 1). Patients in clinical response/remission with trough levels 
in range and no or low ADAs continued at previous dose and in-
terval, while those in clinical remission with low trough levels and 
high ADAs stopped IFX therapy. Those in clinical response/remis-
sion with low trough levels and no or low ADAs had their dosing 
intensified, while in those with high trough levels dosing was de-
creased. Patients with active symptoms and inflammation with low 
trough levels and high ADAs were switched to an alternative anti-
TNF, while those patients with active symptoms and inflammation 
having normal trough levels were switched to a non-anti-TNF bi-
ologic. For 54 patients, the initial decision was altered based on the 
results of TDM. Subsequent TDM measurements were taken pro-
actively after a further 2 infusions for patients whose IFX dosing 
or frequency was altered, or reactively if a loss of response oc-
curred. This study is a 12-month follow-up subsequent to these 
virtual biologic clinical decisions using retrospectively collected 
data. All TDM in the initial study was based on proactive testing 
of the whole IFX cohort using a drug-sensitive assay as previously 
described when TDM first became available to our service [13].
Data Collection
We collected data concerning the 12-month clinical and eco-
nomic impacts of the final decisions, in light of results of TDM, 
made in the MDT. In order to achieve this, all encounters with the 
IBD service (outpatient clinical appointments, IBD helpline con-
tacts, and inpatient admissions), IBD-related investigations (en-
doscopy or cross-sectional imaging), and biologic drug adminis-
tration data were extracted from the hospital’s electronic patient 
record. As follow-up was in the year 2016–2017, all prices for IBD 
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service encounters and investigations were based on 2016 NHS 
reference pricing. Costs for biologic drugs were obtained from the 
hospital pharmacy, and the costs of day-case administration of in-
travenous preparations, provided by the hospital finance team, 
were added to these. For the year 2016–2017, the IFX biosimilar 
CT-P13 was used routinely, while adalimumab, vedolizumab, and 
ustekinumab were used as originator products. Medication prices 
have substantially changed since 2016 in the UK, and to give an 
accurate picture of the costs that are now applicable, a further anal-
ysis of costs as applicable in 2020 was performed.
Outcomes and Analysis
The primary outcome of interest was the clinical course in the 
group where the first decision was altered based on the results of 
TDM (“change” group) versus the group of patients where the de-
cision was unaltered (“no change” group) despite subsequent 
knowledge of TDM results. For this, we defined inpatient admis-
sions and/or the need for a subsequent switch in biologic therapy 
as relevant clinical events. Secondary outcomes included the over-
all health-care costs of the change group compared with the no 
change group. We also conducted subgroup analyses, where we 
divided the change group and no change groups into 4 subgroups: 
IFX stopped (I), IFX switched to an alternative biologic (II), IFX 
continued with an adjusted dose or interval (III), and IFX contin-
ued at same dose and interval (IV).
Data were first presented in a descriptive manner. Categorical 
data were analysed using a χ2 test. Continuous data were analysed 
with t tests for normally distributed, and Mann-Whitney test for 
non-normally distributed, continuous variables. Not all treatment 
decisions made within the MDT were implemented by the respon-
sible clinicians. Data were therefore analysed based on whether the 
MDT’s decision was actually implemented (analogous to a per 
protocol analysis used in clinical trials). Analyses based on the 
MDT’s decision, irrespective of whether it was implemented (anal-
ogous to an intention-to-treat (ITT) analysis), were also conduct-
ed. Statistical significance was set at 1%, and the analysis was per-
formed with SPSS version 22 (SPSS Inc., Chicago, IL, USA). As a 
clinical audit using routinely collected clinical data, this study is 
exempt from the need for ethics committee approval [15].
Results
Of 191 patients included in the previous study, 4 were 
excluded as patient records were unavailable. A total of 
187 (55% men, age range 18–86 years [mean 40 years, 
standard deviation 14]) patients were therefore included 
in this study. In total, 53 (28.3%) patients had their initial 
treatment decision altered following knowledge of TDM 
results. A total of 134 (71.6%) patients initial treatment 
decisions remained unaltered after knowledge of TDM 
results. Details of the treatment decisions made were pre-
viously published [13]. Over 80% of MDT-recommended 
decisions altered in light of knowledge of results of TDM 
were instigated by the responsible clinician.
Primary Outcome as per Implemented Decision
There were no differences in the primary clinical out-
comes between the change and no change groups. In 53 
patients with a decision that was altered based on the re-
sults of TDM, 3 inpatient admissions (5.7%) occurred, 
compared with 15 (11.1%) in the no change group (p = 
0.40). The rate of subsequent biologic switches was 1 
(1.9%) in the change and 2 (1.5%) in the no change group 








































Fig. 1. Treatment algorithm for IFX based on TDM. IFX, infliximab; TDM, therapeutic drug monitoring; IBD, 
inflammatory bowel disease; ADA, anti-drug antidody.
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(p = 1.00). There were no significant differences in the 
percentage of patients requiring imaging investigations 
(27.7 vs. 31.8%; p = 0.73) or endoscopies (22.2 vs. 21.5%; 
p = 1.00) in the change and no change groups.
Secondary Outcomes
Total IBD-related health-care costs were higher in the 
change group (median GBP 7,912 vs. GBP 6,521; p < 
0.0001). The extra costs related mainly to costs for a 
switch in medication from a biosimilar IFX to originator 
products of adalimumab, vedolizumab, or ustekinumab 
or an associated increase in day-case administration costs 
due to adjustments in IFX interval (median GBP 7,062 vs. 
GBP 6,012; p < 0.0001).
To account for recent reductions in costs of biosimilar 
IFX and a considerable reduction in costs for adalimum-
ab due to the arrival of biosimilar adalimumab, we per-
form a further analysis with medication costs as applica-
ble in 2020. At current medication prices, the median 
overall health-care cost for the change group would have 
been similar to the unchanged group (GBP 5,105 vs. GBP 
5,060; p = 0.87). The cost of medication and medication 
administration were also similar (changed GBP 5,235 vs. 
unchanged GBP 4,603; p = 0.88).
Subgroup Analyses
Decision to Stop IFX (Subgroup I)
In the change group, 8 patients stopped IFX as they 
were in clinical remission despite unfavourable TDM 
(low trough levels and high ADAs). None were subse-
quently hospitalized or were switched to an alternative 
biologic. In the no change group who stopped IFX, one of 
4 patients were hospitalized, and no patients were 
switched (p = 0.33 and p = 1.00, respectively). The median 
average 12-month cost for all IBD-related care was high-
er for the no change group (GBP 2,427.65) than the 
change group (GBP 607.25). This numerical difference 
did not reach statistical significance (p = 0.38). The drug 
and day-case administration costs were, however, higher 
in the no change group (GBP 1,214.10 vs. GBP 318.25; 
p = 0.048, Table 1).
Decision to Switch to a Different Biologic  
(Subgroup II)
Of 14 patients in the change group that were switched 
from IFX to a different biologic, none were subsequently 
hospitalized or switched to another biologic. By compar-
ison, in the no change group, 1 of 2 patients was hospital-
ized, but none were subsequently switched to a different 
biologic (p = 0.13 and p = 1.00, respectively). In the change 
group, median average 12-month costs for all IBD-relat-
ed care were lower than in the no change group (GBP 
9,815.30 vs. GBP 13,175.00; p = 0.02). This difference was 
also seen for drug and day-case administration costs 
(GBP 9,548.00 change vs. GBP 11,181.10 no change; p = 
0.02).
Adjusted IFX Dose or Infusion Interval  
(Subgroup III)
None of 25 patients with dose or interval adjusted 
IFX in the change group experienced a hospitalization 
or switch to another biologic. In contrast, 3 of 21 pa-
tients in the no change group with dose or interval ad-
justed IFX were hospitalized, but none had their bio-
logic subsequently switched (p = 1.00). Total IBD-relat-
ed health-care costs were lower in the change group than 
the no change group (GBP 7,220.00 vs. GBP 7,823.98; 
p < 0.001). Drug and day-case administration costs were, 
however, significantly higher for the change group than 
the no change group (GBP 7,168.80 vs. GBP 6,403.95; 
p < 0.001), due to the adjustments in IFX interval and 
dosing.
Continue at Same IFX Dose and Interval  
(Subgroup IV)
In the change group, 3 out of 6 patients were hospital-
ized and 1 patient required a subsequent switch to an al-
ternative biologic. In the no change group, 10 out of 107 
(9.3%) patients were hospitalized and 2 (1.9%) subse-
quently switched to an alternative biologic. The differ-
ences in hospitalization rates were lower in the no change 
group (p = 0.02). This effect was only seen in the analysis 
as by decisions implemented by clinicians. The 4 patients 
experiencing those events were continued on an unal-
tered dose of IFX as the MDT suggestions that incorpo-
rated the TDM results were not implemented by the treat-
ing clinician (Table  2). There was no statistical signifi-
cance between the 2 groups for subsequent switch to a 
different biologic during the following 12 months (p = 
0.15). Overall health-care costs in the change group were 
significantly higher than the no change group (GBP 
8,486.05 vs. GBP 7,454.65; p < 0.001). Drug and day-case 
administration costs were also higher for the change 
group than the no change group (GBP 7,454.65 vs. GBP 
6,001.60; p < 0.001).
Factors Associated with Inpatient Admission
To determine whether IFX levels and ADA levels at 
baseline were associated with the need for hospitalization, 
we compared median IFX trough levels (2.85 subsequent-
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ly hospitalized vs. 3.2 subsequently not hospitalized pa-
tients; p = 0.74) and median IFX ADAs (0 in those requir-
ing admission vs. 0 not requiring admission; p = 0.62). 
Following implementation of the decisions of the virtual 
biologics clinic, median IFX levels during monitoring 
over the 12 months were 3.25 in those requiring admis-
sion and 3.2 in those not (p = 0.49). The median ADA 
level was 0 in those requiring admission versus 0 in those 
not (p = 0.45).
Discussion
The role of routine proactive TDM for all patients re-
ceiving IFX therapy, rather than those only experiencing 
secondary loss of response, is not fully established [8]. We 
have shown previously that knowledge of TDM results 
led to changes in decision-making at an annual assess-
ment in a virtual biologics clinic in almost 30% of patients 
[13]. Our follow-up study confirms that decisions made 
based on the results of TDM provide clinically durable 
results without risking adverse patient outcomes. This 
should reassure clinicians who are concerned about alter-
ing clinical decisions based on the results of TDM for pa-
tients who are in clinical remission. In addition, we show 
that this was associated with a modest increase in health-
care expenditure.
Our study was performed when IFX was purchased at 
much reduced prices as a biosimilar product, but adalim-
umab, vedolizumab, and ustekinumab were all purchased 
at much higher originator prices. There may now be sav-
ings to be made, as at the time of our study, biosimilar IFX 
was used, but any patient switched to adalimumab would 
have been switched to the originator, with the associated 
full price costs. The introduction of biosimilar adalim-
umab in 2019 has drastically reduced the price, and so any 
patient switched to adalimumab would now have reduced 
drug expenditure, while during the 2016 study period, a 
switch to adalimumab would have increased drug-related 
costs. Indeed, when we performed an analysis based on 
drug prices from 2020, we found no difference in costs 
between changed and unchanged groups.
We have demonstrated the key clinical outcomes were 
no different between the change and no change groups 
overall. We used objective outcomes of inpatient admis-
sions and a switch to another biologic therapy in a real-
world study. This supports the use of routine IFX TDM 
to inform proactive clinical decisions, in addition to the 
established use of TDM in the setting of treatment failure. 
Our data show that in a subset of patients with unfavour-
able TDM results, and who are in clinical remission, IFX 
can be safely stopped without adverse outcomes or the 
need for a different biologic. In addition, in patients in 
clinical remission with high trough levels, we have been 
able to reduce dosing accordingly. Our current practice is 
to proactively measure TDM after completion of induc-
tion with the 4th infusion and annually thereafter. In ad-
dition, for any patient experiencing loss of response, we 
use TDM reactively.
Naturally, when looking at specific subgroups of pa-
tients, some differences were observed. We found a sig-
nificant difference in hospitalization rates for the sub-
group of patients with IFX continued at the current dose 
and interval. Here, patients with a decision altered by the 
results of TDM fared worse than those with decisions un-
changed, albeit based on very small numbers. This effect 
was only seen in patients where the MDT suggestion to 
change treatment based on TDM was not implemented 
by the treating clinician.
The main strengths of our study include that we exam-
ined the whole cohort of IFX patients at our institution 
with proactive TDM. The cohort was also previously na-
ïve to TDM as this only became available at our institu-
tion in 2016. Furthermore, we blinded the decision mak-
ers to the TDM results initially to reduce bias in decision-
making.
There are a number of important limitations to our 
study. Firstly, this is a single centre experience, and clin-
ical decision-making may vary from centre to centre. 
Secondly, the retrospective study design allowed for cap-
ture of all health-care encounters at our institution, but 
we could not collect any encounters that may have oc-
curred outside our institution. We also did not record 
encounters with primary care. Thirdly, in a rapidly 
changing health-care market, drug-related costs change 
continually, with variations between different regions 
and countries. These results may therefore not be univer-
sally applicable. Finally, our study cannot establish 
whether TDM-based decision-making in virtual biolog-
ics clinic is superior to the previous, clinically based driv-
en, standard of care. In our centre, a comparator group, 
who were not exposed to TDM, did not exist. We instead 
chose to compare outcomes with the no change group. 
We would have expected that this group of patients 
would do particularly well as the group consisted pre-
dominantly of patients with a combination of favourable 
TDM, a favourable response to IFX, and a clinical indica-
tion to continue IFX. If anything, this group would be 
expected to have better, not worse, outcomes than the 
change group. However, in order to determine whether 
Therapeutic Drug Monitoring of 
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TDM-based management is superior to the previous 
standard of care a clinical trial comparing previous stan-
dard of care management with proactive TDM would 
have to be much larger than the TACIT study to have 
sufficient power to detect clinically meaningful differ-
ences in outcome [9]. Given the resources required to 
perform such a study, it is doubtful such a study would 
ever be performed. In conclusion, our study demon-
strates that the use of results of TDM, in conjunction 
with routine information such as biochemistry, imaging, 
endoscopic, and clinical assessment, to make decisions 
concerning whether to adjust or stop IFX therapy in pa-
tients with IBD can safely influence management, with-
out negatively affecting patient outcomes, such as in-
creased hospitalization or requirement for a further 
switch of biologic treatment.
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